Sur180 Therapeutics develops non-hormonal therapeutics for endometriosis by targeting the hypothalamic-pituitary-adrenal (HPA) axis. The company is advancing a drug candidate, a CRHR1 antagonist, to address the root causes of pain and lesion biology in the condition. This approach offers an evidence-based alternative to current treatment paradigms for this widespread gynecologic disorder.
Funding
$371K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Endometriosis, a condition where tissue similar to the uterine lining grows outside the uterus, lacks effective long-term, non-hormonal treatment options, often leading to repeated surgical interventions and a diminished quality of life for affected women. Current treatments frequently rely on hormone therapies that may have undesirable side effects or are not suitable for all patients. The need for alternative therapeutic approaches that address the underlying causes of endometriosis and provide lasting relief remains unmet.
Solution
Sur180 Therapeutics is developing novel small molecule therapeutics targeting the corticotropin-releasing hormone (CRH) system to treat endometriosis. Their approach involves repurposing CRH antagonists, a family of compounds that modulate the body's stress response, which has been implicated in the development of endometriosis. By targeting CRH receptors in the uterus, ovaries, and endometrium, Sur180 aims to provide a non-hormonal therapeutic option that reduces or eliminates the need for surgical interventions. In addition to pharmacological approaches, Sur180 is also exploring non-pharmacological complementary treatment options that target the stress system to improve outcomes for women with endometriosis.
Target Audience
The primary target audience includes women diagnosed with endometriosis, healthcare providers specializing in gynecology and women's health, and investors interested in supporting innovative therapeutic solutions for gynecological conditions.
Features
- Repurposing of CRH antagonists for endometriosis treatment
- Targets the stress system's role in endometriosis development
- Aims to reduce or eliminate surgical interventions
- Non-hormonal therapeutic approach
- Exploring non-pharmacological complementary treatment options
- Research projects funded by the National Institutes of Health (NIH)